TIMP metalloproteinase inhibitor 3
TIMP3proteinTIMP3 inhibition of matrix metalloproteinases protects fibrous-cap integrity, preventing plaque rupture and thrombotic occlusion.
Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleMMP inhibitor preventing fibrous-cap degradation; directly stabilizes plaque and prevents rupture-driven thrombosis.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000100234
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I42
C — confounder / Type-II59
A — assay feasibility68
E — evidence strength23
T1DI (composite)6
Specificity differential (R−C)-17.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease.BMC medicine · 2023 · PMID 38049831 · doi